Efficacy of Sarcupyrine/valsartan in the treatment of acute myocardial infarction: a meta-analysis.

Objective: To assess the efficacy of sacubitril-valsartan in the treatment of acute myocardial infarction (AMI) using meta-analysis methods.

Methods: Relevant papers on sacubitril/valsartan for treating AMI were searched on PubMed, Embase, Medical Literature Analysis, and Retrieval System On-Line (MEDLINE), Science Direct, The Cochrane Library, Chinese National Knowledge Infrastructure (CNKI), Wanfang Database, Chinese Scientific Journal Database, and Chinese Biomedical Literature Database (CBM). The time range was from their inception to February 1, 2023.

Results: A total of 10 articles involving 13,135 patients were included for this meta-analysis according to the inclusion and exclusion criteria. Among these patients, 6,581 were treated with sacubitril/valsartan, as the experimental group, and the other 6,554 patients were classified into the control group. After treatment, the risk of hospitalization for heart failure (HF) in the experimental group was lower than that of the control group (OR=0.77, 95% CI: 0.67-0.88, P=0.0002); the average left ventricular end diastolic diameter (LVEDD) (MD=-5.56, 95% CI: -7.92-3.20, P<0.0001) was significantly higher and 6-minute-walk distance (6MWD) (MD=95.86, 95% CI: 30.57-161.16, P=0.004) was significantly longer in the treatment group than in the control group. Besides, the left ventricular ejection fraction (LVEF) (MD=2.99, 95% CI: 0.47-5.51, P=0.02) was significantly lower than that of the control group.

Conclusion: Sacubitril/Valsartan improves cardiac function in patients with AMI, reduces the risk of postoperative myocardial reinfarction, and reduces the risk of hospitalization for HF.